| Literature DB >> 33088164 |
Jing Zhang1, Liu-Cun Gao2, Shu Guo3, Tian-Lu Mei3, Jin Zhou3, Guo-Li Wang3, Fei-Hong Yu3, Yong-Li Fang3, Bao-Ping Xu4.
Abstract
BACKGROUND: Pancreaticopleural fistula (PPF) is a rare disease, especially in children. Conservative treatment and surgery are traditional therapies, but surgery is invasive. The emergence of endoscopic retrograde cholangiopancreatography (ERCP) has provided a new noninvasive treatment for PPF and may become the first choice for children with PPF. AIM: To explore the treatment response to ERCP for PPF in children.Entities:
Keywords: Childhood; Diagnostic; Endoscopic retrograde cholangiopancreatography; Magnetic resonance cholangiopancreatography; Pancreaticopleural fistula; Treatment
Mesh:
Year: 2020 PMID: 33088164 PMCID: PMC7545396 DOI: 10.3748/wjg.v26.i37.5718
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Laboratory findings in patients with pancreaticopleural fistula
| 1 | Bloody | 300 | 40.0 | 6625 | 1026 | 3912.9 | 13053.0 |
| 2 | Bloody | 560 | 34.0 | 10477 | 423 | 1051 | - |
| 3 | Bloody | 3600 | 40 | 3178 | 409 | 950 | - |
| 4 | Bloody | 1700 | 17.4 | 50465 | 284-654 | 355.4 | - |
| 5 | Bloody | 800 | 45 | 1584 | 110 | 4470 | - |
| 6 | Bloody | 1200 | 27.6 | 65000 | 1368 | 1312.2 | |
| 7 | Bloody | 6 | 46.7 | 25549 | 738 | 731.2 | - |
Clinical symptoms, treatments, and outcomes of seven children with pancreaticopleural fistula
| Age (yr) | 8 | 10 | 3 | 2 | 5 | 8 | 10 |
| Gender | Male | Female | Male | Male | Female | Female | Female |
| Symptom | Fatigue, poor appetite, intermittent fever, abdominal distention | Intermittent chest tightness and upper abdominal pain | Chronic pancreatitis, recurrent abdominal pain | Wheezing, shortness of breath, repeated bloody pleural effusion | Abdominal pain for half a year, fever and chest tightness | Intermittent chest tightness and dyspnea for more than 20 d | Chest pain with dyspnea |
| Etiology | Suspected trauma and pseudocyst | Dilatation and calculus of pancreatic duct | Congenital pancreatic duct dysplasia and pseudocyst | Pseudocyst and dilatation of pancreatic duct | Pseudocyst and dilatation of pancreatic duct | Dilatation and calculus of pancreatic duct | Pancreatic duct stone, pseudocyst, dilatation of pancreatic duct |
| Diagnosis | laboratory examination, B ultrasound, MRCP | laboratory examination, MRCP | laboratory examination, enhanced CT, MRC, ERCP | laboratory examination, CT, B ultrasound, MRCP | laboratory examination, CT, B ultrasound, MRCP | laboratory examination, CT, MRCP, ERCP | laboratory examination, CT, B ultrasound, MRCP |
| Location of pleural effusion | Right | Bilateral | Bilateral | Left | Right | Bilateral | Right |
| Amylase in pleural effusion (U/L) | 6625 | 10477 | 3178 | 50465 | 1584 | 65000 | 25549 |
| Conservative treatment time (d) | 10 | 21 | 60 | 24 | 19 | 20 | 10 |
| ERCP treatment | Yes (Surgical treatment after ERCP failure) | No (Operation) | Yes | Yes | No (Operation) | Yes | Yes |
| Serum amylase concentration before operation (U/L) | 889.4 | 153 | 367 | 429 | 93.0 | 292 | 283 |
| Serum amylase concentration after operation (U/L) | 102 | 267 | 315 | 105 | 110 | ||
| Time for amylase to return to normal (Days after operation) | 23 | 10 | 9 | 4 | |||
| Lipase concentration before operation/ERCP (U/L) | 567 | 1051 | 355.4 | 115 | 106 | 731.2 | |
| Lipase concentration after operation/ERCP (U/L) | 51.7 | 62.4 | |||||
| Stop somatostatin pump maintenance time (days after operation) | 19 | 5 | 3 | 4 | |||
| Postoperative recovery time of eating (days after operation) | 3 | 3 | 6 | 6 | 4 | 15 | |
| Times of fever treated conservatively | 1 | 3 | 5 | 3 | 4 | Normal temperature | |
| Chest closed drainage time (days after operation) | - | - | 16 | - | - | - | |
| Postoperative hospital stay (d) | 20 | 30 | 30 | 12 | 12 | 23 | |
| Total length of stay (d) | 30 | 52 | 90 | 36 | 32 | 33 |
CT: Computed tomography; ERCP: Endoscopic retrograde cholangiopancreatography; MRCP: Magnetic resonance cholangiopancreatography.
Comparison of therapeutic effect of endoscopic retrograde cholangiopancreatography vs conservative treatment
| 1 | 10 | 20 | 30 | |||||||
| 2 | 21 | 31 | 52 | |||||||
| 5 | 19 | - | ||||||||
| 3 | 60 | 30 | 19 | 6 | 23 | 367 | 292 | 30 | 90 | |
| 4 | 24 | 12 | 5 | 6 | 10 | 267 | 249 | 12 | 36 | |
| 6 | 20 | 12 | 3 | 4 | 9 | 429 | 283 | 12 | 32 | |
| 7 | 10 | 23 | 4 | 15 | 4 | 315 | 110- | 23 | 33 | |
| Average (ERCP) | 34.67 ± 22.03 | 18 ± 10.39 | 9 ± 8.72 | 5.33 ± 1.15 | 14 ± 7.81 | 344.5 ± 69.58 | 233.5 ± 84.39 | 25.5 ± 7.78 | 18 ± 10.39 | - |
The second day after endoscopic retrograde cholangiopancreatography (ERCP) stent placement, the patient had poor drainage of the pancreatic stent outflow tract because of stone blockage. This made it difficult to control the secondary infection, and the hospitalization time was prolonged. This patient was not included in the statistical analysis.
Surgical treatment.
ERCP treatment. ERCP: Endoscopic retrograde cholangiopancreatography.
Figure 1The correlation between endoscopic retrograde cholangiopancreatography intervention time and total hospital stay. The linear equation is not a model prediction but only a correlation analysis.
Worldwide cases of pancreaticopleural fistula published in the most recent 10 years
| Adult | ||||||
| 2009[ | F/52 | CT/MRCP | Conservative/ERCP | 14 | 7 | |
| 2009[ | M/46 | MRCP | Conservative/ERCP | 27 | 14 | |
| 2010[ | F/44 | CT | Conservative/operation | 5 | ||
| 2012[ | M/64 | B ultrasound/ERCP | Conservative/ERCP | |||
| 2012[ | F/52 | CT | Conservative/operation | |||
| 2012[ | M/58 | CT/ERCP | Conservative/operation | 42 | ||
| 2013[ | F/47 | CT | Conservative | |||
| 2013[ | M/59 | CT/ERCP | Conservative | 56 | ||
| 2013[ | F/58 | CT/MRI | Conservative/ERCP | 7 | 12 | |
| 2016[ | F/65 | CT/MRCP | Conservative/operation | 21 | ||
| 2014[ | F/50 | CT/MRCP | Conservative/ERCP/operation | |||
| 2014[ | M/49 | CT/MRCP/MRI | Conservative/operation | |||
| 2015[ | M/43 | CT/ERCP | Conservative/operation | 35 | 10 | |
| 2015[ | M/43 | CT/MRCP | Conservative/ERCP/operation | 28 | ||
| 2016[ | M/58 | CT | Conservative/ERCP | |||
| 2016[ | M/51 | CT/ERCP/MRI | ERCP | 21 | ||
| 2016[ | F/51 | CT/MRCP | Conservative/operation | 28 | 5 | |
| 2016[ | F/63 | CT/MRCP | Conservative/operation | 30 | ||
| 2016[ | M/78 | CT | Conservative | |||
| 2017[ | M/44 | MRCP | Conservative/ERCP | |||
| 2017[ | M/52 | CT/MRCP | Conservative | |||
| 2018[ | M/49 | CT/MRCP/ERCP | Conservative/ERCP | |||
| 2019[ | M/52 | Operation | Conservative/ERCP | 21 | ||
| 2019[ | M/35 | CT | Conservative/ERCP | 14 | 20 | |
| 2019[ | M/65 | CT/MRCP/ERCP | Conservative/operation | |||
| Children | ||||||
| 2009[ | M/4 | CT/MRCP | Conservative/ERCP | 60 | 30 | |
| 2013[ | F/5 | CT | Conservative | 50 | ||
| 2013[ | M/15 | CT/MRI | Conservative/ERCP | 28 | ||
| 2014[ | M/2.5 | B ultrasound/CT | Conservative/operation | 26 | 11 | |
| 2014[ | M/8 | CT | Conservative | 60 | ||
| 2014[ | M/2 | CT | Conservative | |||
| 2016[ | M/2 | CT | operation | |||
| 2018[ | F/8 | CT/MRCP | Conservative/ERCP | 17 | 19 | |
| 2018[ | F/14 | CT/MRCP | Conservative/operation | 30 | ||
| 2019[ | M/3 | CT/MRCP | Conservative/ERCP | 18 | ||
| 2019[ | F/8 | CT/MRCP | Conservative/ERCP | 8 | 18 | |
| 2019[ | M/14 | CT | Conservative/operation | 30 | ||
| AVG | 30.76 ± 17.4 | 16 ± 10.95 | 18.7 ± 6.88 | |||
CT: Computed tomography; ERCP: Endoscopic retrograde cholangiopancreatography; MRCP: Magnetic resonance cholangiopancreatography; MRI: Magnetic resonance imaging.